Neurocrine BiosciencesLTS:0K6R +2.55%96 EBITDA Margin % is 23.73% as of Mar. 2026, which is 78% above its 10-year median of 13.32. GuruFocus rates LTS:0K6R with a GF Score™ of 96/100 and a GF Value™ of $186.61 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 952 Drug Manufacturers companies, Neurocrine Biosciences ranks better than 80.36% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Neurocrine Biosciences EBITDA Margin % Related Terms
Neurocrine Biosciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Neurocrine Biosciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0K6R vs VTRS, ELAN, RGC: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurocrine Biosciences EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Neurocrine Biosciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurocrine Biosciences (LTS:0K6R) has a EBITDA Margin % of 23.73% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Neurocrine Biosciences and its competitors. This is 78% above median its historical median of 13.32. According to the industry distribution chart, Neurocrine Biosciences ranks #187 out of 952 companies in the Drug Manufacturers industry, placing it in the top 19.6%.
Is Neurocrine Biosciences' EBITDA Margin % too high?
Neurocrine Biosciences' current EBITDA Margin % of 23.73% is 78% above median its 10-year median of 13.32. The Drug Manufacturers industry median EBITDA Margin % is 12.47. Neurocrine Biosciences' value of 23.73% is 90.3% above this industry median. Based on the distribution chart, Neurocrine Biosciences ranks #187 out of 952 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Neurocrine Biosciences has a GF Score™ of 96/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' EBITDA Margin % compare to VTRS and ELAN?
According to the Drug Manufacturers industry distribution chart, Neurocrine Biosciences ranks #187 out of 952 companies for EBITDA Margin %. This places Neurocrine Biosciences in the top 20% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 12.47. Neurocrine Biosciences' value of 23.73% is 90.3% above this benchmark. While the company's 10-year median is 13.32 vs. the industry median of 12.47, Neurocrine Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.47, based on 952 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neurocrine Biosciences's current EBITDA Margin % of 23.73% is 90.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Neurocrine Biosciences and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurocrine Biosciences's current EBITDA Margin % is 23.73%, which is 78% above median its own 10-year median of 13.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (LTS:0K6R) is currently considered Modestly Undervalued. The stock's GF Value™ is $186.61, compared to a current price of $168.12 — trading 9.9% below its estimated fair value. The current EBITDA Margin % is 23.73%, which is 78% above median its 10-year median of 13.32 and 90.3% above the Drug Manufacturers industry median of 12.47. Neurocrine Biosciences' overall GF Score™ is 96/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Neurocrine Biosciences (LTS:0K6R), the current EBITDA Margin % is 23.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neurocrine Biosciences (LTS:0K6R) Overvalued in 2026?
Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued.
The current stock price of $168.12 is trading 9.9% below its estimated GF Value™ of $186.61.
GuruFocus considers Neurocrine Biosciences to be Modestly Undervalued.
Key valuation signals for LTS:0K6R:
EBITDA Margin %: 23.73% (78% above median its 10-year median of 13.32)
GF Value™: $186.61 vs. price of $168.12 (9.9% below fair value)
Industry Position: 90.3% above the Drug Manufacturers median (#187 of 952)
No single metric tells the full story. See the LTS:0K6R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
96GF Score
Get the complete analysis for LTS:0K6R
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0K6R has been successfully added to your 
